Introduction
A key role in the development of cancer of the uterine cervix has been attributed to oncogenic human papillomavirus (HPV) types such as HPV-16, 18, 31 and 33 (zur Hausen, 1994) . The lack of an effective immune response to HPV-induced premalignant and malignant cervical lesions has been considered an important factor in the development and progression of cervical cancer (Duggan-Keen et al., 1994) . This hypothesis is supported by the increased occurrence of cervical intraepithelial neoplastic (CIN) lesions in patients with compromised cellular immunity such as HIV-seropositive individuals and renal transplant recipients (Halpert et al., 1986; Sch/ifer et al., 1991; Laga et al., 1992) . Jan H. H, Walboomers. Fax +31 20 4442964. e-mail pathol@azvu.nl Both cellular and humoral immune responses have been detected against several HPV proteins in murine and human studies (Cubie & Norval, 1988; Cubie et al., 1989; Strang et aI., 1990; Tindle et al., 1991; Steele et a] ., 1993). HPV-16 E7 is expressed in both premalignant lesions and cervical cancer and in vivo experiments in mice have demonstrated that it can function as a tumour rejection antigen (Chen et aI., 1991; Feltkamp et al., 1993) . These characteristics make E7 an attractive antigen for the study of HPV-16-specific immunity in women with abnormal cervical cytology.
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Serological studies have led to the identification of an immunodominant region in the N terminus of the HPV-I6 E7 protein (Mhller et aI., 1992) . HPV-type specific IgG responses against this region were found in a high frequency in cervical cancer patients, but until now not in patients with premalignant lesions (Mhller et al., i992; Suchankova eta] ., 1992; Viscidi et al., 1993) . This leaves the importance of these responses for the clinical outcome of CIN disease unclear. Several human T helper (Th)-cell epitopes in HPV-16 E7 have been identified in previous studies and recently E7-specific proliferative responses have been found in CIN patients (Altmann et al., 1992; Kadish et a/., 1994) . These responses were most frequently present in patients with an ongoing infection of either or the related HPV types 31 and 33 (Kadish et al., 1994) . The role of these responses in the clearance of viral infection and the regression of CIN lesions remains to be elucidated, A possible role can be inferred from a follow-up study of patients with abnormal cervical cytology recently reported by our group (Remmink et al., 1995) . A strong relationship was found between persistence of oncogenic HPV types and progression of premalignant cervical lesions. In contrast, the absence of progression was often found to be associated with HPV clearance or fluctuation (Remmink et al., 1995) . Fluctuating HPV patterns may point to continual reinfection followed by clearance due to ongoing immune responses. Clearance of HPV infection and a subsequent regression of the cervical lesion may result from a successful immune response while a persisting infection could be due to a failing immune response.
The aim of this study was to analyse in HPV-16-positive CIN patients from this cohort Th responses in relation to the status of the HPV infection, i.e. a persistent, a cleared or a fluctuating HPV infection pattern. It was found that in patients with a persistent HPV-16 infection and progressive cervical lesions, relatively high frequencies of apparently ineffective ET-specific Th cells were present.
Methods
• Patients. Patients involved in this study were referred to the gynaecological outpatient clinic of the Free University Hospital in Amsterdam because of abnormal cervical cytology (at least Pap 3a) and, after informed consent, participated in a prospective follow-up study carried out as a combined effort of the Departments of Obstetrics and Gynaecology and Pathology to evaluate the natural history of CIN lesions in relation to HPV status. The patients were examined every 3-4 months by colposcopy and cervical smears were taken for HPV genotyping and cytology (Remmink et aI., I995) . Results from the cytomorphological tests were classified according to a modified Papanicolaou system as employed in the Netherlands: Pap 1, no cytomorphological abnormalities; Pap 2, inflammation; Pap 3a, mild to moderate dyskaryosis; Pap 3b, severe dyskaryosis; Pap 4, carcinoma in situ; Pap 5 (microinvasive) carcinoma. In order to avoid any interference in the natural history of the CIN lesions no biopsies were taken during follow-up. Based on cytological and colposcopical observations patients were recognized as having either progressive (Pr), regressive (R) or stable (S) CIN disease (Remmink et al., 1995) . Biopsies of the lesions were taken and histologically characterized when patients left the cohort study due to patients' refusal or progression. For a detailed description of the study design and clinical evaluation we refer to Remmink et al. (I995) .
A subgroup of 51 patients aged 23-55 was selected and divided into five different test groups on the basis of their HPV status over time up until the moment of lymphocyte proliferation testing (Tab|e 1). As HPV-16 E7-specific IgG reactivity serves as an indication of previous E7-specific Th activity, we also determined plasma IgG reactivity against the immunogenic region aa 6--35 of HPV-16 E7 in a peptide-based ELISA. HPV-negative patients with low reactivity were selected for the negative control group, while HPV-positive patients were selected with both weak and strong HPV-16 ET-specific IgG responses (see Table 1 ).
A total of 26 HPV-16-positive patients with a persistent, a cleared or a fluctuating infection were studied.
The HPV-16 Persistence (P) group consisted of patients who were consistently found HPV-I6 positive by PCR over a period of at least 12 months prior to testing (n = 9). Colposcopical and cytological evaluation showed this group to consist of patients with stable and progressive CIN lesions ( Table 1) .
The HPV-16 Clearance (C) group consisted of patients who tested HPV negative for at least 12 months after they were previously typed positive for HPV-I6 (n = 9). Patients in this group showed mostly regressive CIN lesions ( Table I) .
The HPV-16 Fluctuation (F) group was made up of patients with neither HPV-16 persistence nor clearance but with a fluctuating HPV-16 infection pattern (n = 8). These patients had either stable or regressive CIN lesions (Table 1) .
The HPV Negative (N) patients (n = 15) were consistently typed HPV negative during the entire period of follow-up and for at least 12 months prior to testing. This group of patients presented mainly with regressive lesions (see Table 1 ).
Also, a group of patients with ongoing or cleared infections of an HPV type Other than -16 (O) was tested (n = 10). Clinically, this was a heterogeneous group of patients with progressive, stable and regressive CIN lesions (Table 1) .
The two latter groups served as negative controls for HPV and HPVtype specificity respectively of the responses detected in the HPV-16-positive test groups. All patient groups were age matched.
• HPV genotyping, HPV detection and genotyping were performed on cellular material from cervical smears as described elsewhere (Remmink et al., 1995; Van den Brule et al., 1990) . Briefly, cells obtained from cervical smears were collected in PBS--O'05% Merthiolate, pelleted, resuspended in 1 ml I0 mM-Tris (pH 7'5), and frozen at -70 °C. For PCR 10 I~l aIiquots were taken. This suspension was boiled for 10 min, cooled on ice, and centrifuged for 1 min at 3000 g, before being used in an HPV general primer-mediated PCR (GP-PCR). GP-PCR-positive samples were further tested in a type-specific PCR (TS--PCR) for the relatively common genital HPV types 6, II, 16, 18, 31 and 33. GP-PCR products of samples that turned out negative in the TS--PCR were stringently and successively hybridized after GP-PCR to full-length cloned DNA from genital HPV genotypes 13, 30, 32, 35, 39, 40, 42, 43, 44, 45, 51, 52, 54, 55, 56, 57, 58, 59, 61 and 66 (De Roda Husman et al., 1994) . HPV GP-PCR-positive smears that could not be identified in this manner were called HPV-X.
• Expression and partial purification of the glutathione Stransferase-E7 fusion protein. E7 open reading frame cloned into the prokaryotic expression vector pGEX-3X was kindly provided by H. Smits and J. ter Schegget, Academic Medical Center, University of Amsterdam. In the resulting protein, HPV-16 E7 was fused to the carboxyl terminus of glutathione S-transferase from Schistosoma japonicum. Growth of transformed E, coli and induction of expression was performed as previously described (Smith & Johnson, 1988) . The glutathione S-transferase-E7 fusion protein (GST-ET, ±42 kDa) was isolated and partially purified from E. coil Bacteria were lysed by suspension in a solution of 100 mM-NaC1, 20 mM-Tris-HC1 (pH 8"0), I mM-EDTA, and 0'5 % (w/v) NP40 and subsequent sonification on ice. After centrifugation, glutathione-agarose beads (Sigma) were added to the supematant and left on ice for 60 rain. The bound fusion protein was IgG reactivity against HPV-16 E7/aa6--35 in a peptide based ELISA graded according to observed absorbance values as follows: A4~ 2 0--0"3 (--), A¢9 ~ 0"3--0"6 (+), A¢92 0'6--0"9 (+ +), A4s 2 > 0"9 (+ + +). § Disease status based on cytological and colposcopical observations: Pr, progressive lesion; S, stable lesion; R, regressive lesion. 11 Histological examination performed on biopsies taken at a later time-point from patients leaving the cohort study (C1N 0, no lesion discernible; CIN I, mild dysplasia; CIN II, moderate dysplasia; CIN III, severe dysplasia/carcinoma in situ). eluted from the agarose beads with 5 mM-reduced glutathione (Sigma) at room temperature. The purified proteins were analysed by PAGE and subsequent immunoblotfing was performed with a guinea-pig polyclonal antiserum to confirm the expression of E7. The polyclonal antiserum was raised against a trpE fusion protein containing HPV-16 E7 (a kind gift of D. Galloway, Hutchinson Cancer Research Center, Seattle, Wash., USA).
• Synthetic peptides. The HPV-16 E7 sequence was covered by 14 synthetic peptides consisting of 20 residues with an overlap of 14 amino acids (see Fig. 1 ). The pepfides were synthesized with a Millipore 9050 peptide synthesizer using the Fmoc method, dissolved in DMSO to a stock concentration of 10 mM and further diluted in culture medium.
• Preparation of peripheral blood mononuclear cells (PBMC) and plasma. PBMC were isolated from 40 ml of heparinized blood by density centrifugation with Lymphoprep (Nycomed) and cryopreserved in RPMI 1640 medium supplemented with 0"01 M-HEPES buffer, 50 U/ml penicillin-streptomycin and 1"6 mM-L-glutamine, containing 10% DMSO and 10% FCS. Prior to harvesting the PBMC from the Lymphoprep layer, 3 ml of plasma (I : 1 diluted in PBS, 0'5 % BSA) was removed and stored at -20 °C for serological tests.
• Generation of short-term T cell lines. Per donor 5-10 x 10 e PBMC were seeded in round-bottom 96-well culture plates (Costar) at a concentration of 2 x 105 cells per well in Iscove's modified Dulbecco's medium containing 10 % human pooled serum (HPS) (CLB, Amsterdam), 50 U/ml penicillin-streptomycin, 1'6 mM-L-glutamine and 0'01 mM-]~-mercaptoethanol. Cells were cultured for 14 days at 37 °C in an incubator with a 5 % CO~ humidified atmosphere, in the presence of I ,g/ml of the GST-E7 bacterial fusion protein. At day 7 of culture the cells received 25 IU/ml rIL-2 (Cetus, Amsterdam). After 2 weeks a split well analysis was performed to determine E7-specific proliferation. Results were expressed as the percentage of responding wells. Reproducibility tests of the culture method gave consistent results with variations of no more than 20 %. FACS experiments after the 2 week culture period showed the tested cells to be of a CD3+/CD56 phenotype with approximately 20 % expressing CD8 and 60% expressing CD4 at the cell surface.
• Split-well lymphocyte proliferation test (LPT). • Peptide ELISA for the detection of E7-specific IgG reactivity.
Plasma from the tested patients was used to determine seroreactivity against the N-terminal immunodominant epitope aa 6--35 of HPV-I6 E7 described by Muller et al. (1992) . ELISA plates (Maxisorp; Nunc) were coated with a 30-mer synthetic peptide covering aa 6--35 (a kind gift of P. Herbrink, SSDZ, Delft, the Netherlands). The peptide was dissolved in an Na2CO3-NaHCOa coating buffer (pH 9"6) at a concentration of 20 ~g/ml. Coating was carried out overnight at 37 °C with 50 i11 per well. Subsequently, the plates were washed three times with PBS containing 0"1% Tween 20 (PBST) and blocked for 2h at room temperature with PBST-I0% FCS. Subsequently, the plates were incubated for 2 h at room temperature with plasma 1 : 5 and 1 : 10 diluted in PBST-FCS (100 ~l). After washing five times with PBST, 100 ~1 of peroxidase-labelled rabbit anti-human IgG (Dako) diluted 1:1000 in PBST-FCS was added per well. The plates were left for I h at room temperature and again washed five times with PBST. Finally, 0"2 g/ml Ophenylenediamine (Dako) dissolved in a KH2SO4-Na2PO4 buffer containing H20 2 was added (100 gl/we[1). The reaction was stopped by the addition of 100 ~l 2 M-H2SO 4 per well. Subsequently, the absorbance at 492 nm (A492) was measured using an ELISA plate reader.
• Statistical analysis. Percentages of positively responding cell lines between groups were analysed using the Mann-Whitney U test. The mean value of the HPV-negative patient group plus three times the standard deviation was calculated and used as a cut-off value. Patients with a percentage of positively responding cell lines exceeding this value were considered to have a positive proliferative response against HPV-16 E7. The proportions of positive responders between the different :18( i !i i ii iiiiiiiJiiJiJi J iiii patient groups were then compared using Fisher's exact test. P values below 0'05 were considered statistically significant.
Results

Detection of T cell proliferative responses against HPV-16 E7
PBMC proliferation in five HPV-16-positive patients was determined against different concentrations of pools of 20-mer overlapping peptides covering the E7 sequence in a standard 7 day LPT. None of the tested patients showed any E7-specific reactivity which was considered to be indicative of a low frequency of E7-specific T cells in the peripheral blood. We therefore decided on an alternative protocol. For each patient multiple short-term T cell lines were generated from PBMC by culturing 2 x 105 cells per well in a round-bottom 96-well plate in the presence of a GST-E7 bacterial fusion protein over a period of 14 days. We thus expected to amplify the frequency of ET-specific T cells in the cultures. Subsequently, E7-specific proliferation was determined in each of the cell lines against the total pool of E7 synthetic peptides in a 3 day LPT. E7 reactivity was then expressed as the percentage of T cell lines in which specific proliferation was detected. This percentage can be regarded as a reflection of the original frequency of E7-specific T cells present in the total PBMC pool of the tested patients. Examples of proliferative results from a standard 7 day LPT and from short-term cell lines are shown in Fig. 2 . On day 7 no ET-specific proliferation could be detected for either patient N12, who was consistently typed HPV negative over a period of 38 months prior to proliferation testing, or for patient P1, who had had a persistent HPV-16 infection for over 29 months at the time of testing (Fig. 2a) . After 14 days of culture in the presence of GST-E7, patient N12 showed hardly any E7-specific proliferation (10% reactive cell lines), whereas patient P1 now showed specific proliferation in a considerable number of the tested cell lines (74%) (Fig. 2 b) . Also, the stimulation indices in patient P1 were considerably higher. From these results we conclude that E7-reactive T cells are indeed present in the peripheral blood of patients with HPV-16 infection but at very low frequencies. Apparently, a prolonged culture period is required for the detection of ET-specific T cell proliferation. This proliferation appears to originate from memory T cells primed in vivo, because in naive lymphocytes from umbilical cord blood we were unable to detect any E7-specific proliferation when using the same protocol (data not shown).
HPV-16 E7-specific T cell proliferation in relation to HPV status
Proliferative responses against HPV-I6 E7 for the HPV- Percentages of responding T cell lines in the HPV-16-positive group (mean 21"0 %) were signifcantly higher than in both the HPV-negative (mean 3"2 %, P < 0"000I) and the HPV non-16 group (mean 7"1%, P ----0-006), showing the observed T cell proliferation to be HPV-type specific. Interestingly, the mean percentage of positively responding T cell lines was considerably higher in the patients with a persisting HPV-I6 infection (30"1%), as compared to patients with either a cleared infection (17"0%) or a fluctuating HPV-16 pattern (15"5%) (P ---0"05). In this context it is of interest that the only HPV non-I6-positive patient with a positive T cell proliferative response also had a persistent infection (O1, HPV-33, Table 1 ).
The mean percentage of the HPV-negative group plus three times the standard deviation resulted in a cut-off value of 16"4%. Patients with percentages of E7 reactive cell lines exceeding this value were considered to be positively responding to HPV-16 E7. As shown in Table 2 , the resulting proportions of positive responders in the different patient groups also confirmed the type-specificity of the proliferative responses in the HPV-16-positive group and showed these responses to be most prominent in patients with persistent infections.
HPV-16 E7-specific T cell proliferation in relation to
HPV-16 E7/aa 6-35 IgG reactivity
No clear correlation was observed between HPV-16 E7-specific T cell proliferation and IgG reactivity. In the HPV-I6-positive group (combined P, C and F groups) 6/13 patients with moderate to high IgG reactivity (+ to + + + ) showed positive T cell responses exceeding the cut-off value, while 9/13 IgG negative (-) patients also showed T cell reactivity (Fig. 3) . Apparently, E7-specific IgG reactivity in these patient groups is not predictive for the presence or absence of E7-specific T cell proliferation. However, the presence of IgG reactivity does at least imply previous Th cell activity. As 5/9 clearance patients showed no HPV-16 ET-specific T cell proliferation, but three of these did show IgG reactivity against HPV-16 E7/aa 6-35 (C1, C2 and C3; Fig. 3) , this raises the possibility that in these patients proliferative T cell responses were present at the actual time of clearance but that they have since declined over time.
Discussion
In this study, we have demonstrated the presence of HPV-16 ET-specific memory Th cells in the peripheral blood of CIN patients with a current or past HPV-16 infection. The percentage of women with positive proliferative responses turned out to be significantly higher in patients with a persistent HPV-16 infection presenting with stable or progressive cervical lesions as compared to patients with either a cleared or fluctuating HPV-16 infection and stable or regressive cervical lesions. Although the presence of HPV-16 E7-specific !iiiiiiiiiiiiiiii!ii ! :i ii E i'ii iiiiB iiii iii i iii;:i :ii! iiiii!iiii!ii!ii!i.iiiii Table 2 . Positive responders to Comerford et al., 1991; Shepherd et al., 1992; Cubie et a]., 1989; Strang eta] ., 1990). HPV-16 ET-specific Th cell responses may play a vital role in regulating and directing cytotoxic T cell responses to HPV-16-infected and E7-expressing keratinocytes in the basal layers of the cervical epithelium. Altmann eta] . (1992) generated several HPV-16 E7-specific CD4 + T cell lines and clones from peripheral blood of healthy women with serological reactivity to an E7 fusion protein and Kadish et aI. (I994) showed HPV-16 E7-specific proliferation in CIN patients.
Due to generally low frequencies of HPV-specific T cells circulating in peripheral blood, most Th cell studies in healthy women or CIN patients have had to rely on restimulation protocols to detect any HPV-specific proliferation (Strang et al., 1990; Kadish et al., 1994) . We were able to detect HPV-16 E7-specific proliferative responses in PBMC with a split-well test after one restimulation with overlapping peptides covering the E7 sequence. The presence of responses to E7 in HPV-16-positive but not in HPV-negative patients strongly suggests that the detected proliferation originates from memory T cells and is not generated by priming of T cells in vitro. This is further supported by the fact that we were unable to detect any E7-specific proliferation in the naive T cell population of umbilical cord blood when using the same protocol. Recently, a restimulation protocol in multiple short-term T cell lines, similar to the method we have used in this study, was described as a means to estimate antigen specific T cell frequencies (Manca et al., 1995) . Thus, the observed frequencies of E7-responsive cell lines in our tests can be regarded as a reflection of the frequency of ET-reactive T cells in the blood of the tested patients.
We observed significantly higher E7-specific T cell frequencies in patients with persistent HPV-16 infections and clinically progressive lesions as compared to patients with cleared or fluctuating infections and minor, stable or regressing lesions. Higher T cell reactivity during persistence may be due to higher expression levels of E7 and consequently more E7-derived epitopes being presented in the context of MHC molecules. Low proliferative responses but high IgG reactivities observed in some patients with HPV-16 clearance seem to indicate that E7-specific Th cell frequencies were higher at one time but waned with the passage of time after clearance. These data suggest that the maintenance of T cell memory is dependent on continuous antigenic stimulation. These findings are consistent with observations made by Kadish et al. (1994) who found high proliferative responses in 3 week T cell lines against a C-terminal peptide covering aa 72-97 of the HPV-16 E7 sequence in patients with an ongoing infection with HPV-16 or closely related types. Moreover, seroreactivity against the same peptide was found in HPV-negative patients without proliferative responses who might have had a cleared viral infection. Although based on a different culture method and reactivity against a different B cell epitope, these data do fit in with our observations of low T cell proliferation and continued seroreactivity after viral clearance.
A significant difference was also found between the HPV-16 group and the HPV non-16 group in the frequency of women with positive proliferative responses, thus confirming the type-specificity of the detected responses ( Table 2 ). The one positive responder in the non-16 group had a persistent infection with HPV-33, a type closely related to . This is in keeping with the observation by Kadish et al. (1994) that beside HPV-16 positive women, HPV-31 or -33 positive women also showed HPV-16 E7-specific proliferative responses. In contrast to proliferative responses, IgG reactivity against HPV-16 E7/aa 6--35 was not found to be strictly typespecific in our study (Table 1) . IgG reactivity against HPV-16 E7/aa 6-35 was previously found to be HPV-16-associated in invasive carcinoma but this association has not yet been established in CIN patients (MLiller et aL, 1992) .
An association between high T cell frequencies and progression of papillomavirus-induced lesions is further corroborated by a recent report of in vivo experiments in a rabbit model where high proliferative responses against cottontail rabbit papillomavirus (CRPV) were only detected when CRPV-induced papillomas progressed to carcinoma (Selvakumar et al., 1994) . This is in agreement with our !i i observation that high HPV-16 E7-specific T cell frequencies in the peripheral blood of patients with HPV-16 persistence and high grade cervical lesions seem to indicate ineffective cellular immune responses. However, T cell and/or IgG reactivity in a number of patients with a cleared infection suggest a past cellular immune response that did prove effective. Several possible explanations for this apparent dichotomy in the effect of the observed T cell responses in patients with virus clearance or persistence exist. First, genetic factors may be involved. Certain MHC haplotypes may be more effective in raising an HPV-16-specific immune response while others may have negative effects (Apple et al., 1994) . Second, downregulation of MHC-I molecules in HPV-induced cervical lesions may hamper cellular immune effector functions, even in the presence of high HPV-specific T cell frequencies (Cromme et al., 1993; Duggan-Keen et al., 1994) . Finally, the observed dichotomy can also be explained by a differential production of Th cytokines. Effective viral immunity is characterized by a well-balanced production of both Thl and Th2 cytokines, while chronic viral infections are more often accompanied by a shift in the Thl/Th2 balance to a more Th2-1ike response (Biron, 1994; Clerici & Shearer, 1993) . With rising CIN grade, increased MHC-II expression on keratinocytes lacking appropriate co-stimulatory signals may result in a preferential activation of Th2 cells, thus interfering with the induction of effective antiviral Thl and CTL responses (Cromme et al., 1993; Glew et aL, 1992; Ba] et aL, 1990; Goodman ef al., 1994; Muller et al., 1994) . We are now pursuing these lines of investigation to identify the relevant factors determining the outcome of HPV-16-specific immune responses.
In conclusion, we have shown HPV-16 E7-specific memory T cells to be present in CIN patients with persistent, cleared and fluctuating HPV-16 infections, but not in HPV-negative patients. Highest Th cell responses were found in patients with a persistent infection and stable or progressive cervical lesions, indicating that continuous presence of E7 is necessary for the maintenance of memory Th cell responses and that these responses are not in themselves predictive of the outcome of HPV-16 infection. Apparently, other determining factors are involved. Longitudinal lymphoproliferative studies in the same cohort of patients are now underway to confirm and elaborate on these findings.
